Asset profile
Vemurafenib
Small molecule
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2026-10-31.
NCT02314481: This is a non-randomized, single-group study without blinding or a comparator arm, with 50 participants distributed across several treatment groups. Its primary endpoints are progression-free and overall survival, but results are not posted, so there is no reported comparison showing whether vemurafenib was effective.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
October 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchNovember 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchDecember 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2027 (1)
December 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2029 (1)
October 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.